Cargando…
Enantiospecific Pharmacogenomics of Fluvastatin
The aim of this study was to investigate how variability in multiple genes related to pharmacokinetics affects fluvastatin exposure. We determined fluvastatin enantiomer pharmacokinetics and sequenced 379 pharmacokinetic genes in 200 healthy volunteers. CYP2C9*3 associated with significantly increas...
Autores principales: | Hirvensalo, Päivi, Tornio, Aleksi, Neuvonen, Mikko, Kiander, Wilma, Kidron, Heidi, Paile‐Hyvärinen, Maria, Tapaninen, Tuija, Backman, Janne T., Niemi, Mikko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767327/ https://www.ncbi.nlm.nih.gov/pubmed/30989645 http://dx.doi.org/10.1002/cpt.1463 |
Ejemplares similares
-
Pharmacogenomics of celiprolol – evidence for a role of P‐glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics
por: Hirvensalo, Päivi, et al.
Publicado: (2021) -
Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics
por: Hirvensalo, Päivi, et al.
Publicado: (2017) -
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics
por: Lehtisalo, Minna, et al.
Publicado: (2022) -
Performance of Plasma Coproporphyrin I and III as OATP1B1 Biomarkers in Humans
por: Neuvonen, Mikko, et al.
Publicado: (2021) -
Genomewide Association Study of Simvastatin Pharmacokinetics
por: Mykkänen, Anssi J. H., et al.
Publicado: (2022)